• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail
?
-

Resources for You

BK120021 Letter

 

Immucor, Inc.
Attention: Mr. Howard Yorek
3130 Gateway Drive
P.O. Box 5625
Norcross, GA 30091
 
Re:                              BK120021
Device Name:             TPHA Screen
Regulation Number:    21 CFR§866.3830
Regulation Name:        Treponema pallidum treponemal test reagents
Regulatory Class:        Class II
Product Code:             MYR
Dated:                       October 18, 2012
Received:                    October 18, 2012
 
Dear Mr. Yorek:
 
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act ( the Act) that do not require approval of a premarket approval application (PMA).  You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: FDA does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
 
If your device is classified (see above) into either Class II (Special Controls) or Class III (PMA), it may be subject to additional ontrols. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
 
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR 807); labeling (21 CFR 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality system (QS) regulation (21 CFR 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
 
If you desire specific advice on promotional labeling and advertisement for your device, please contact our Advertising and Promotional Labeling Staff (HFM-602) at (301) 827-3028.  Also, please note the regulation entitled,"Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR 803), please go to: http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
 
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638‑2041 or (301) 796-7100 or at its Internet address: http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
 
If you have questions concerning this letter, please contact Cherie Ward-Peralta, Regulatory Project Manager, at (301) 827-9170.
 
Sincerely yours,
 
 /s/
 
Hira L. Nakhasi, Ph.D.
Director
Division of Emerging and
 Transfusion Transmitted Diseases
Office of Blood Research and Review  
Center for Biologics
 Evaluation and Research
 
 

 
Indications for Use  
 
 
510(k) Number:          BK120021
 
Device Name:             TPHA Screen
 
Indications for Use:
 
The TPHA Screen is intended for use in the qualitative screening of blood donors for the detection of IgG and IgM antibodies to Treponema pallidum in human serum and EDTA plasma by passive hemagglutination using the Galileo and/or Galileo Neo, Automated Blood Bank Systems.